Skip to content
Screener

Neuropace, Inc. NPCE Q4 2025 Annual earnings

Reported March 3, 2026 · After market close

Revenue$26.6MBeat by $1.8M
EPS-$0.08Beat by $0.06
Revenue estimate$24.7M
EPS estimate-$0.14

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$27.1M
EPS estimate-$0.11

Financials

Q4 2025

Income statement

See full
Revenue$26.6M+23.9%
Gross profit$20.6M+27.1%
Operating income-$1.8M+51.6%
Net income-$2.7M+48.0%
EPS (diluted)-$0.08+52.9%

Balance sheet

See full
Cash & equivalents$21.8M+61.0%
Total debt$70.8M-3.4%
Total equity$19.0M+138%
Total assets$105.6M+11.5%

Cash flow

See full
Operating cash flow-+100%
CapEx$97.0K+149%
Free cash flow-+100%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$514.27M+54.0%
Enterprise value$563.29M+43.0%
P/S5.4×+1.2×

Profitability

See full
Gross margin78.5%+4.5pp
Operating margin-18.4%-4.5pp
Net margin-22.4%-5.7pp
FCF margin-12.2%-3.9pp

Returns & leverage

See full
Return on equity-158.7%-22.1pp
Debt / equity3.7×-5.4×
Current ratio5.3×-0.1×

FAQ

When did Neuropace, Inc. report Q4 2025 earnings?
Neuropace, Inc. (NPCE) reported Q4 2025 earnings on March 3, 2026 after market close.
What were Neuropace, Inc.'s Q4 2025 revenue and EPS?
Neuropace, Inc. reported revenue of $26.6M and eps of $-0.08 for Q4 2025.
Did Neuropace, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $24.7M by $1.8M. EPS beat the consensus estimate of $-0.14 by $0.06.
How did Neuropace, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 23.9% from $21.5M a year earlier and eps grew 55.6% from $-0.18.
Where can I find Neuropace, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001528287-26-000008) and the 10-K periodic report (0001528287-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.